Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

11726 results about "Anti oxidant" patented technology

A kind of non-aqueous electrolytic solution for lithium secondary battery

The invention relates to a non-aqueous electrolytic solution used for lithium secondary batteries, in particular to an electrolytic solution capable of improving the high-voltage cycle performance of lithium batteries and the storage performance of the electrolytic solution. The non-aqueous electrolytic solution disclosed by the invention contains 0.01-2% by weight of antioxidant based on the total weight of the electrolytic solution, and due to the incorporation of the additives, the storage stability of the electrolytic solution is obviously improved. The non-aqueous electrolytic solution also contains lithium salt, a non-aqueous organic solvent and also contains the following components in percentage by total weight of the electrolytic solution of 0.5-7 percent of film-forming additives, 0-15 percent of flame-retardant additives, 2-10 percent of overcharge protection additives, 0.01-0.02 percent of a stabilizing agent and 0.01-1 percent of a wetting agent. According to the non-aqueous electrolytic solution provided by the invention, batteries can stably work under the high voltage of 4.3V or above, due to the synergic action of the incorporated additives with various functions, the high-capacity lithium-ion batteries can bring high specific energy into full play and have outstanding safety and high-temperature performances and cycle life.
Owner:JIUJIANG TINCI ADVANCED MATERIALS CO LTD

Methods of treating chronic inflammatory diseases using carbonyl trapping agents

InactiveUS6444221B1Improved therapeutic propertyImprove propertiesBiocidePeptide/protein ingredientsEtiologyBenzoic acid
These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).
Owner:SECANT PHARMA

Composition and method for treating impaired or deteriorating neurological function

A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and/or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining methyl metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurological function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and/or a cognitive retraining program, and/or a dietary program designed to maximize insulin and glucose metabolism.
Owner:MCCLEARY EDWARD LARRY

Solid golf ball

The invention provides a solid golf ball having a solid core and a cover layer that encases the core and has an outermost layer on an outside surface of which are formed a plurality of dimples. The solid core is formed of a rubber composition composed of 100 parts by weight of a base rubber that includes from 60 to 100 parts by weight of a polybutadiene rubber having a cis-1,4 bond content of at least 60% and synthesized using a rare-earth catalyst, from 0.1 to 5 parts by weight of an organosulfur compound, an unsaturated carboxylic acid or a metal salt thereof, an inorganic filler, and an antioxidant. The solid core has a deformation, when compressed under a final load of 130 kgf from an initial load of 10 kgf, of from 2.0 to 4.0 mm, and has a specific hardness distribution. The cover layer has a thickness of from 0.5 to 1.9 mm, and a Shore D hardness at the surface of from 50 to 70. The ball has at least one intermediate layer between the core and the cover, any one of which intermediate layer or layers has a surface hardness in Shore D units of from 40 to 60, the intermediate layer or layers having a total thickness of from 0.9 to 7.0 mm. The golf ball has a deformation, when compressed under a final load of 130 kgf from an initial load of 10 kgf, of from 2.0 to 3.8 mm. The solid golf ball is advantageous overall in competitive use.
Owner:BRIDGESTONE SPORTS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products